JPWO2022213204A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022213204A5 JPWO2022213204A5 JP2023561783A JP2023561783A JPWO2022213204A5 JP WO2022213204 A5 JPWO2022213204 A5 JP WO2022213204A5 JP 2023561783 A JP2023561783 A JP 2023561783A JP 2023561783 A JP2023561783 A JP 2023561783A JP WO2022213204 A5 JPWO2022213204 A5 JP WO2022213204A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- inhibitor
- alkyl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171955P | 2021-04-07 | 2021-04-07 | |
| US63/171,955 | 2021-04-07 | ||
| PCT/CA2022/050536 WO2022213204A1 (en) | 2021-04-07 | 2022-04-07 | Combination therapies including myt1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024514844A JP2024514844A (ja) | 2024-04-03 |
| JP2024514844A5 JP2024514844A5 (https=) | 2025-04-03 |
| JPWO2022213204A5 true JPWO2022213204A5 (https=) | 2025-04-03 |
Family
ID=83544890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561783A Pending JP2024514844A (ja) | 2021-04-07 | 2022-04-07 | Ｍｙｔ１阻害剤を含む併用治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240207300A1 (https=) |
| EP (1) | EP4319752A4 (https=) |
| JP (1) | JP2024514844A (https=) |
| CN (1) | CN117729920A (https=) |
| CA (1) | CA3214900A1 (https=) |
| WO (1) | WO2022213204A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12435090B2 (en) | 2021-10-04 | 2025-10-07 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use |
| CN119451958A (zh) * | 2022-07-12 | 2025-02-14 | 微境生物医药科技(上海)有限公司 | 作为myt1抑制剂的化合物 |
| KR20250094718A (ko) * | 2022-11-08 | 2025-06-25 | 제노 매니지먼트, 인크. | Wee1 억제제로 암을 치료하기 위한 예측 바이오마커로서 시클린 e1 상태의 용도 |
| WO2024104282A1 (zh) * | 2022-11-14 | 2024-05-23 | 捷思英达控股有限公司 | 一种1H-吡咯并[2,3-b]吡啶衍生物、其制备方法及其在医药上的应用 |
| EP4624471A4 (en) * | 2022-11-25 | 2026-03-18 | Shanghai Qilu Pharmaceutical Res And Development Centre Ltd | PKMYT1 INHIBITOR, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION, AND ITS USE |
| JP2025542335A (ja) * | 2022-12-22 | 2025-12-25 | リペア セラピューティクス インコーポレイテッド | Ｍｙｔ１阻害剤である２－アミノ－１－（３－ヒドロキシ－２，６－ジメチルフェニル）－５，６－ジメチル－１Ｈ－ピロロ－［２，３－ｂ］ピリジン－３－カルボキサミドを作製する方法 |
| WO2024153249A1 (zh) * | 2023-01-20 | 2024-07-25 | 杭州英创医药科技有限公司 | 作为pkmyt1抑制剂的化合物 |
| WO2024160683A1 (en) * | 2023-01-30 | 2024-08-08 | Ecole Polytechnique Federale De Lausanne (Epfl) | Pou5f1b inhibitors |
| WO2024179948A1 (en) * | 2023-02-28 | 2024-09-06 | F. Hoffmann-La Roche Ag | Indazole compounds as pkmyt1 kinase inhibitors |
| AU2024231943A1 (en) * | 2023-03-09 | 2025-10-16 | Cancer Research Technology Limited | Biarylamide derivatives and their use as pkmyt1 inhibitors |
| TW202444721A (zh) * | 2023-05-12 | 2024-11-16 | 智擎生技製藥股份有限公司 | 稠合吡咯環或稠合吡啶環之化合物 |
| CN121358735A (zh) * | 2023-07-04 | 2026-01-16 | 杭州领业医药科技有限公司 | Rp-6306的晶型及其制备方法和用途 |
| WO2025040014A1 (zh) * | 2023-08-18 | 2025-02-27 | 英矽智能科技知识产权有限公司 | 并环化合物及其制备方法和用途 |
| IL326854A (en) * | 2023-09-14 | 2026-04-01 | Debiopharm Int Sa | Combination of WEE1 inhibitor and PKMYT1 inhibitor |
| WO2025060975A1 (en) * | 2023-09-18 | 2025-03-27 | Insilico Medicine Ip Limited | Novel compounds as pkmyt1 inhibitors and use thereof |
| WO2025074271A1 (en) * | 2023-10-02 | 2025-04-10 | Repare Therapeutics Inc. | Myt1 inhibitors for the treatment of cancers harboring replication stress mutations |
| WO2025074275A1 (en) * | 2023-10-02 | 2025-04-10 | Repare Therapeutics, Inc. | Combination therapies including myt1 inhibitors and wee1 inhibitors |
| WO2025106635A1 (en) * | 2023-11-15 | 2025-05-22 | Zeno Management, Inc. | Alteration of f-box and wd repeat domain containing 7 (fbxw7) gene as a predictive biomarker for treating cancer with wee1 inhibitors |
| KR20250088374A (ko) * | 2023-12-08 | 2025-06-17 | 인제대학교 산학협력단 | Ezh2 저해제 및 mettl3 억제제를 포함하는 암의 예방 또는 치료용 약제학적 조성물 |
| WO2025182927A1 (ja) * | 2024-02-27 | 2025-09-04 | 中外製薬株式会社 | Ｍｙｔ１阻害剤の用途 |
| WO2025188680A1 (en) * | 2024-03-04 | 2025-09-12 | Cardiff Oncology, Inc. | Use of plk1 inhibitor in combination of gemcitabine or carboplatin in treating ovarian carcinoma |
| WO2025237957A1 (en) * | 2024-05-14 | 2025-11-20 | Institut Curie | Composition for treatment of estrogen-dependent cancer comprising a mettl-3 inhibitor and a topoisomerase-1 inhibitor |
| US20260034078A1 (en) | 2024-07-31 | 2026-02-05 | Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud | Xpg inhibitor compounds and the use thereof in the treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000033837A2 (en) * | 1998-12-07 | 2000-06-15 | Smithkline Beecham Corporation | Myt1 kinase inhibitors |
| WO2016104777A1 (ja) * | 2014-12-26 | 2016-06-30 | 国立大学法人九州大学 | がんの処置のための方法 |
| CN115811976A (zh) * | 2020-04-01 | 2023-03-17 | 修复治疗公司 | 使用myt1抑制剂的方法 |
| BR112022019611A2 (pt) * | 2020-04-01 | 2022-11-29 | Repare Therapeutics Inc | Compostos, composições farmacêuticas e métodos para preparar compostos e seu uso |
-
2022
- 2022-04-07 WO PCT/CA2022/050536 patent/WO2022213204A1/en not_active Ceased
- 2022-04-07 CN CN202280040614.5A patent/CN117729920A/zh active Pending
- 2022-04-07 US US18/284,614 patent/US20240207300A1/en active Pending
- 2022-04-07 JP JP2023561783A patent/JP2024514844A/ja active Pending
- 2022-04-07 EP EP22783740.8A patent/EP4319752A4/en active Pending
- 2022-04-07 CA CA3214900A patent/CA3214900A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022213204A5 (https=) | ||
| JP2021534124A5 (https=) | ||
| EP3704098B1 (en) | Modulators of the integrated stress pathway | |
| ES2925564T3 (es) | Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos | |
| EP3704125B1 (en) | Modulators of the integrated stress pathway | |
| AU2018358157B2 (en) | Modulators of the integrated stress pathway | |
| JP2017528498A5 (https=) | ||
| JP7126947B2 (ja) | 抗ウイルス剤によるｂ型肝炎ウイルスの排除 | |
| JP2016534148A5 (https=) | ||
| JP2026009987A (ja) | 統合的ストレス経路の調節剤としての置換シクロアルキル | |
| CN112166113A (zh) | 整合应激通路的调节剂 | |
| JP2007529421A5 (https=) | ||
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| CN112204006A (zh) | 整合应激通路的调节剂 | |
| JP2016526540A5 (https=) | ||
| JP2006504624A5 (https=) | ||
| CA2972014A1 (en) | Fused pyrimidine compounds for the treatment of hiv | |
| JP2010502751A5 (https=) | ||
| JP2019510796A5 (https=) | ||
| WO2015172128A1 (en) | Methods and compositions for treating hepatitis b virus infections | |
| CN112218850A (zh) | 整合应激通路的调节剂 | |
| CN112218851A (zh) | 整合应激通路的调节剂 | |
| CN101142198A (zh) | 用于治疗疾病的异唑坎布雷它斯丁衍生物 | |
| JP2012524731A5 (https=) | ||
| ATE383358T1 (de) | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren |